In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide

M. Fevzi Ozkaynak, Jan Nolta, Robertson Parkman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The outcome of patients with advanced stage rhabdomyosarcoma is extremely poor, with a disease-free survival of <20% at 3 years. Autologous bone marrow transplantation for patients with Clinical Group IV rhabdomyosarcoma may be an effective therapy. The bone marrow involvement diagnosed by light microscopy is 29% for patients with advanced disease. The present study was performed to test the ability of 4-hydroperoxycyclophosphamide (4-HC) to eliminate clonogenic rhabdomyosarcoma cells. Four different human rhabdomyosarcoma cell lines were treated in vitro with 4-HC at a concentration of 100 μg/ml. Limiting dilution analysis was performed to detect surviving clonogenic tumor cells. Treatment with 4-HC resulted in 1.7-5.7 log of elimination of clonogenic tumor cells in all four cell lines. Exactly the same log tumor cell kill was obtained after mixing normal human bone marrow mononuclear cells with rhabdomyosarcoma cells. Treatment with 4-HC may be an effective method of eliminating clonogenic rhabdomyosarcoma cells ex vivo.

Original languageEnglish (US)
Pages (from-to)1455-1458
Number of pages4
JournalCancer Research
Volume50
Issue number5
StatePublished - Mar 1 1990
Externally publishedYes

Fingerprint

perfosfamide
Rhabdomyosarcoma
Cell Line
Neoplasms
Autologous Transplantation
Bone Marrow Transplantation
Bone Marrow Cells
Disease-Free Survival
In Vitro Techniques
Microscopy
Therapeutics
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide. / Ozkaynak, M. Fevzi; Nolta, Jan; Parkman, Robertson.

In: Cancer Research, Vol. 50, No. 5, 01.03.1990, p. 1455-1458.

Research output: Contribution to journalArticle

Ozkaynak, M. Fevzi ; Nolta, Jan ; Parkman, Robertson. / In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide. In: Cancer Research. 1990 ; Vol. 50, No. 5. pp. 1455-1458.
@article{b7c68333776f4ababeab409ebf69b293,
title = "In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide",
abstract = "The outcome of patients with advanced stage rhabdomyosarcoma is extremely poor, with a disease-free survival of <20{\%} at 3 years. Autologous bone marrow transplantation for patients with Clinical Group IV rhabdomyosarcoma may be an effective therapy. The bone marrow involvement diagnosed by light microscopy is 29{\%} for patients with advanced disease. The present study was performed to test the ability of 4-hydroperoxycyclophosphamide (4-HC) to eliminate clonogenic rhabdomyosarcoma cells. Four different human rhabdomyosarcoma cell lines were treated in vitro with 4-HC at a concentration of 100 μg/ml. Limiting dilution analysis was performed to detect surviving clonogenic tumor cells. Treatment with 4-HC resulted in 1.7-5.7 log of elimination of clonogenic tumor cells in all four cell lines. Exactly the same log tumor cell kill was obtained after mixing normal human bone marrow mononuclear cells with rhabdomyosarcoma cells. Treatment with 4-HC may be an effective method of eliminating clonogenic rhabdomyosarcoma cells ex vivo.",
author = "Ozkaynak, {M. Fevzi} and Jan Nolta and Robertson Parkman",
year = "1990",
month = "3",
day = "1",
language = "English (US)",
volume = "50",
pages = "1455--1458",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide

AU - Ozkaynak, M. Fevzi

AU - Nolta, Jan

AU - Parkman, Robertson

PY - 1990/3/1

Y1 - 1990/3/1

N2 - The outcome of patients with advanced stage rhabdomyosarcoma is extremely poor, with a disease-free survival of <20% at 3 years. Autologous bone marrow transplantation for patients with Clinical Group IV rhabdomyosarcoma may be an effective therapy. The bone marrow involvement diagnosed by light microscopy is 29% for patients with advanced disease. The present study was performed to test the ability of 4-hydroperoxycyclophosphamide (4-HC) to eliminate clonogenic rhabdomyosarcoma cells. Four different human rhabdomyosarcoma cell lines were treated in vitro with 4-HC at a concentration of 100 μg/ml. Limiting dilution analysis was performed to detect surviving clonogenic tumor cells. Treatment with 4-HC resulted in 1.7-5.7 log of elimination of clonogenic tumor cells in all four cell lines. Exactly the same log tumor cell kill was obtained after mixing normal human bone marrow mononuclear cells with rhabdomyosarcoma cells. Treatment with 4-HC may be an effective method of eliminating clonogenic rhabdomyosarcoma cells ex vivo.

AB - The outcome of patients with advanced stage rhabdomyosarcoma is extremely poor, with a disease-free survival of <20% at 3 years. Autologous bone marrow transplantation for patients with Clinical Group IV rhabdomyosarcoma may be an effective therapy. The bone marrow involvement diagnosed by light microscopy is 29% for patients with advanced disease. The present study was performed to test the ability of 4-hydroperoxycyclophosphamide (4-HC) to eliminate clonogenic rhabdomyosarcoma cells. Four different human rhabdomyosarcoma cell lines were treated in vitro with 4-HC at a concentration of 100 μg/ml. Limiting dilution analysis was performed to detect surviving clonogenic tumor cells. Treatment with 4-HC resulted in 1.7-5.7 log of elimination of clonogenic tumor cells in all four cell lines. Exactly the same log tumor cell kill was obtained after mixing normal human bone marrow mononuclear cells with rhabdomyosarcoma cells. Treatment with 4-HC may be an effective method of eliminating clonogenic rhabdomyosarcoma cells ex vivo.

UR - http://www.scopus.com/inward/record.url?scp=0025373396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025373396&partnerID=8YFLogxK

M3 - Article

C2 - 2302710

AN - SCOPUS:0025373396

VL - 50

SP - 1455

EP - 1458

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -